A carregar...
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?
Idiopathic pulmonary fibrosis is a rare, progressive and fatal lung disease which affects approximately 5 million persons worldwide. Although pirfenidone and/or nintedanib treatment improves patients’ wellbeing, the prognosis of IPF remains poor with 5-year mortality rates still ranging from 70 to 8...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6833050/ https://ncbi.nlm.nih.gov/pubmed/31561518 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8101547 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|